Muhammad Baig

Muhammad Baig

Auto-generated profile, based on publicly available information

Muhammad Baig

Departments of Research and Medicine, Vascular Research Laboratory, Providence VA Medical Center, Providence, Rhode Island, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KNKyari Sumayin Ngamdu
Kyari Sumayin Ngamdu
DGDhairyasheel S. Ghosalkar
Dhairyasheel S. Ghosalkar
HCHojune E. Chung
Hojune E. Chung
JCJared L. Christensen
Jared L. Christensen
CLCadence Lee
Cadence Lee
AMAlan R. Morrison
Alan R. Morrison
Background: Atherosclerosis and consequent risk of cardiovascular events or mortality can be accurately assessed by quantifying coronary artery calcium score (CACS) derived from computed tomography. HMG-CoA-reductase inhibitors (statins) are the primary pharmacotherapy used to reduce cardiovascular events, yet there is growing data that support statin use may increase coronary calcification. We set out to determine the likelihood of severe CACS in the context of chronic statin therapy. Methods: We established a retrospective, case-control study of 1,181 U.S. veterans without coronary artery disease (CAD) from a single site, the Providence VA Medical Center. Duration of statin therapy for primary prevention was divided into 5-year categorical increments. The primary outcome was CACS derived from low-dose lung cancer screening computed tomography (LCSCT), stratified by CACs severity (none = 0; mild = 1–99; moderate = 100–399; and severe ≥400 AU). Statin duration of zero served as the referent control. Ordinal logistic regression analysis determined the association between duration of statin use and CACS categories. Proportional odds assumption was tested using likelihood ratio test. Atherosclerotic cardiovascular disease (ASCVD) risk score, body mass index, and CKD (glomerular filtration rate of <60 ml/min/1.73 m2) were included in the adjustment models. Results: The mean age of the study population was 64.7±7.2 years, and 706 (60%) patients were prescribed a statin at baseline. Duration of statin therapy was associated with greater odds of having increased CACS (>0–5 years, OR: 1.71 [CI: 1.34–2.18], p5–10 years, OR: 2.80 [CI: 2.01–3.90], p10 years, OR: 5.30 [CI: 3.23–8.70], p0–5 years, OR: 1.49 [CI: 1.16–1.92], p = 0.002; >5–10 years, OR: 2.38 [CI: 1.7–3.35], p10 years, OR: 4.48 [CI: 2.7–7.43], p<0.001). Conclusions: Long-term use of statins is associated with increased likelihood of severe CACS in patients with significant smoking history. The use of CACS to interpret cardiovascular event risk may require adjustment in the context of chronic statin therapy.

25 October 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMuhammad Baig
Muhammad Baig
MMMiremad Moafi-Madani
Miremad Moafi-Madani
RQReema Qureshi
Reema Qureshi
MRMary B. Roberts
Mary B. Roberts
MAMatthew Allison
Matthew Allison
CECharles B. Eaton
Charles B. Eaton
Background: Low heart rate variability (HRV), a measure of autonomic imbalance, is associated with increased risk of coronary heart disease (CHD) and heart failure (HF). However, its relationship with HF subtypes; heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) has not been studied prior. Methods and findings: We conducted a longitudinal study in Women’s Health Initiative study cohort to investigate the association of baseline quartiles of resting heart rate (rHR) and HRV measures; SDNN (SD of normal-to-normal RR interval) and RMSSD (root mean square of successive difference of RR interval) measured by twelve-lead electrocardiogram (ECG) on enrollment, with the risk of hospitalized HF and its subtypes. Total of 28,603 post-menopausal women, predominantly non-Hispanic whites (69%), with a mean (SD) age of 62.6 (7.1) years, free of baseline CHD and HF were included. In a fully adjusted cox-proportional hazards regression model which adjusted for age, race, BMI, alcohol intake, education, physical activity, hyperlipidemia, hypertension, left ventricular hypertrophy, use of beta-blocker, calcium-channel blocker, hormone therapy, and time-varying incident CHD, the hazard ratios of lowest quartile of HRV (Q1) with HF risk were significant (Q1 SDNN compared to Q4 SDNN: 1.22, 95% CI 1.07, 1.39; Q1 RMSSD compared to Q4 RMSSD: 1.17, 95% CI 1.02, 1.33). On subgroup analysis of HF subtypes, low HRV was associated with elevated HFpEF risk (Q1 vs Q4 SDNN: 1.22, 95% CI 1.02, 1.47) but not with HFrEF (Q1 vs Q4 SDNN: 1.19, 95% CI 0.95, 1.50; Q1 RMSSD: 1.13, 95% CI 0.90, 1.43). Conclusion: Low HRV is associated with elevated overall hospitalized HF risk and HFpEF risk in post-menopausal women. Whether interventions to increase HRV through healthy lifestyle changes will decrease HF risk warrants further investigation.

7 May 2022 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
MBMuhammad Baig
Muhammad Baig
MKMichael Kwok
Michael Kwok
AAAmmer Aldairi
Ammer Aldairi
HIHafiz M. Imran
Hafiz M. Imran
MKMohammad S. Khan
Mohammad S. Khan
PSPeter A. Soukas
Peter A. Soukas

1 March 2021 in Heart & Lung
Verified
Journal Article
Closed access
MBMuhammad Baig
Muhammad Baig
HIHafiz M. Imran
Hafiz M. Imran
AGArlene Gaw
Arlene Gaw
LSLoren Stabile
Loren Stabile
WWWen-Chih Wu
Wen-Chih Wu

20 May 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
MBMuhammad Baig
Muhammad Baig
MKMichael Kwok
Michael Kwok
AAAmmer Aldairi
Ammer Aldairi
HIHafiz M. Imran
Hafiz M. Imran
MKMohammad Saud Khan
Mohammad Saud Khan
PSPeter A. Soukas
Peter A. Soukas
Common femoral artery (CFA) disease is often heavily calcified and prone to low patency rates with endovascular treatment compared with surgical endarterectomy. Recent data suggest promising short-term outcomes with the adjunct use of intravascular lithotripsy; however, data on its midterm effectiveness are lacking. We compared clinically driven target lesion revascularization (CD-TLR) between patients receiving drug-coated balloon angioplasty with adjunct intravascular lithotripsy (IVL-DCB) vs adjunct atherectomy (Ath-DCB) for treatment of CFA disease. In a single-center retrospective cohort study, patients receiving IVL-DCB vs Ath-DCB for symptomatic CFA disease from January 2015 to March 2020 were included. The primary outcome was cumulative CD-TLR with angiographic restenosis ≥50%, estimated by Kaplan-Meier analysis during 18-month follow-up and compared by log-rank test. Total of 68 CFA lesions (Ath-DCB, 35; IVL-DCB, 33) were included. Patients had a mean age (standard deviation) of 72 (8) years and were predominantly male (63.3%) and White (92%). Mean baseline angiographic stenosis was 78% (11) in the Ath-DCB group and 70% (10) in the IVL-DCB group (P = .002). Technical success was 100% in both groups. One flow-limiting dissection occurred in IVL-DCB requiring stent placement, whereas 2 bailout stentings were performed in the Ath-DCB group. Cumulative Kaplan-Meier freedom from CD-TLR was 91.2% (95% CI, 81.6%-100%) in the Ath-DCB group vs 79.4% (95% CI, 64.6%-94.2%) in the IVL-DCB group (Log-rank P = .167). The safety and effectiveness of IVL-DCB were comparable to those of Ath-DCB in the treatment of calcified CFA disease during the 18-month follow-up. Further studies are required to verify these findings.

14 March 2024 in JEM Reports
Verified
Journal Article
Open access
JHJonie J. Hsiao
Jonie J. Hsiao
MCManuel A. Celedon
Manuel A. Celedon
JRJames L. Rudolph
James L. Rudolph
KKKristin J. Konnyu
Kristin J. Konnyu
SESebhat A. Erqou
Sebhat A. Erqou
EJEric Jutkowitz
Eric Jutkowitz